BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK, Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for...
Source: marketscreener.com